

Yoon-Sim Yap

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2560956/publications.pdf>

Version: 2024-02-01

56
papers

1,792
citations

304602

22
h-index

289141

40
g-index

58
all docs

58
docs citations

58
times ranked

3437
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells. PLoS ONE, 2014, 9, e99409.	1.1	165
2	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. American Journal of Human Genetics, 2018, 102, 69-87.	2.6	144
3	The <i>NF1</i> gene revisited - from bench to bedside. Oncotarget, 2014, 5, 5873-5892.	0.8	139
4	Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nature Medicine, 2017, 23, 1319-1330.	15.2	116
5	Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients. Journal of Clinical Epidemiology, 2014, 67, 811-820.	2.4	94
6	Insights Into Breast Cancer in the East vs the West. JAMA Oncology, 2019, 5, 1489.	3.4	90
7	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. Journal of the National Cancer Institute, 2019, 111, 1298-1306.	3.0	83
8	Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome. JAMA Oncology, 2017, 3, 1538.	3.4	72
9	Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro-Oncology, 2016, 18, 244-251.	0.6	71
10	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Medicine, 2022, 20, 105.	2.3	60
11	Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden. Nature Communications, 2021, 12, 2229.	5.8	49
12	Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. Npj Genomic Medicine, 2016, 1, 15003.	1.7	44
13	Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors. Psycho-Oncology, 2018, 27, 1185-1192.	1.0	42
14	Integrative Analysis and Machine Learning Based Characterization of Single Circulating Tumor Cells. Journal of Clinical Medicine, 2020, 9, 1206.	1.0	42
15	Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. Science Advances, 2021, 7, eabh2443.	4.7	42
16	Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers. Clinical Cancer Research, 2020, 26, 4494-4502.	3.2	38
17	Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1. Cancer Medicine, 2015, 4, 1871-1878.	1.3	30
18	Treating HR+/HER2 ⁻ breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Research and Treatment, 2019, 177, 549-559.	1.1	29

#	ARTICLE	IF	CITATIONS
19	Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. <i>British Journal of Cancer</i> , 2019, 120, 407-423.	2.9	28
20	Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1239-1250.	1.6	27
21	Breast cancer risk in neurofibromatosis type 1 is a function of the type of <i>NF1</i> gene mutation: a new genotype-phenotype correlation. <i>Journal of Medical Genetics</i> , 2019, 56, 209-219.	1.5	26
22	A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5760-5770.	3.2	25
23	A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry. <i>Future Science OA</i> , 2017, 3, FSO244.	0.9	24
24	Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 713-721.	1.1	20
25	Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy. <i>Molecular Neurobiology</i> , 2019, 56, 4741-4750.	1.9	20
26	Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 719-735.	1.1	19
27	Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. <i>Npj Breast Cancer</i> , 2018, 4, 19.	2.3	19
28	Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese. <i>Oncotarget</i> , 2018, 9, 12796-12804.	0.8	19
29	Association of <i>CYP2C19</i> and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1142-1152.	1.1	18
30	Microfluidic studies of hydrostatic pressure-enhanced doxorubicin resistance in human breast cancer cells. <i>Lab on A Chip</i> , 2021, 21, 746-754.	3.1	17
31	Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population. <i>PLoS ONE</i> , 2015, 10, e0134408.	1.1	15
32	Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 665-676.	1.1	15
33	Liquid biopsies for residual disease and recurrence. <i>Med</i> , 2021, 2, 1292-1313.	2.2	15
34	Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform. <i>PLoS ONE</i> , 2019, 14, e0221305.	1.1	14
35	Impact of deviation from guideline recommended treatment on breast cancer survival in Asia. <i>Scientific Reports</i> , 2020, 10, 1330.	1.6	14
36	Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide. <i>Journal of Breast Cancer</i> , 2016, 19, 8.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Identification of Novel Breast Cancer Risk Loci. <i>Cancer Research</i> , 2017, 77, 5428-5437.	0.4	12
38	Impact of Cryotherapy on Sensory, Motor, and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled Trial. <i>Frontiers in Neurology</i> , 2020, 11, 604688.	1.1	12
39	Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 197-206.	1.1	10
40	Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. <i>Future Oncology</i> , 2019, 15, 2489-2501.	1.1	8
41	Assessment of PARP4 as a candidate breast cancer susceptibility gene. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 145-153.	1.1	8
42	Effects of housing value and medical subsidy on treatment and outcomes of breast cancer patients in Singapore: A retrospective cohort study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 6, 100065.	1.3	7
43	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 701-741.	1.7	7
44	Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing. <i>Scientific Reports</i> , 2020, 10, 16774.	1.6	6
45	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1527-1539.	1.3	5
46	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study – An Asian Tertiary Cancer Center Experience. <i>JCO Precision Oncology</i> , 2021, 5, 859-875.	1.5	4
47	Evaluation of brain-derived neurotrophic factor (BDNF) genetic polymorphism (rs6265) on chemotherapy-associated cognitive impairment in early-stage breast cancer (ESBC) patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9616-9616.	0.8	4
48	Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. <i>Clinical and Translational Science</i> , 2021, 14, 1015-1025.	1.5	2
49	Validation of a Risk Score Incorporating Tumor Characteristics into the American Joint Committee on Cancer Anatomic Stage for Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 260.	0.8	2
50	Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience. <i>World Journal of Clinical Oncology</i> , 2020, 11, 283-293.	0.9	2
51	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+ /HER2+ breast cancer. <i>Cancer Research</i> , 2022, 82, GS2-01-GS2-01.	0.4	2
52	Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories. <i>Journal of Breast Cancer</i> , 0, 25, .	0.8	2
53	DNA methyltransferase 1 (DNMT1) polymorphism and chemotherapy-associated cognitive impairment in early-stage breast cancer patients (ESBC): A prospective, longitudinal study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10014-10014.	0.8	1
54	Predictors of hand-foot syndrome (HFS) in randomised double-blind, placebo-controlled trial of pyridoxine for prevention of capecitabine induced HFS.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9596-9596.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Evaluation of pro-inflammatory cytokines and anxiety symptoms in early-stage breast cancer (ESBC) patients: A prospective, longitudinal study.. Journal of Clinical Oncology, 2015, 33, e20742-e20742.	0.8	0
56	Phase Ib/II trial of expanded and activated autologous natural killer (NK) cells with trastuzumab (Tras) in refractory HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, 3045-3045.	0.8	0